Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 8/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.36 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3153297 | 0.95 | CHRM5 (0.39) | CHRM5CHRM3CHRM2CHRM4CHRM1 | |
| SCHEMBL30938358 | 0.84 | CHRNB2 (0.37) | CHRM5CHRM3CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL11490476 | 0.81 | CHRNB2 (0.34) | CHRM5CHRM3CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL8185974 | 0.79 | HTR6 (0.43) | CHRM5CHRM3CHRM2CHRM4CHRM1 | |
| SCHEMBL2552216 | 0.79 | HTR6 (0.39) | CHRM5CHRM3CHRNB2CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL8186266 | 0.77 | HTR6 (0.42) | CHRM5CHRM3CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL8776613 | 0.73 | HSD17B10 (0.41) | L3MBTL1 | |
| Hydrochloric Acid SCHEMBL8776634 | 0.72 | HSD17B10 (0.40) | L3MBTL1 | |
| SCHEMBL15896435 | 0.72 | CHRNB2 (0.39) | CHRM5CHRM3CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL14186218 | 0.71 | HRH3 (0.43) | CHRM5CHRM3CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | CHRM5 450/4885CHRM3 386/4885CHRM2 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.